Table 3.
Proportion of patients with post-diagnosis health services utilization, stratified by alternative bone metastasis measures
| |
Claims Approach 3 |
SEER measure |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Full M1 sample |
Concurrent BM |
No concurrent BM |
|
BM at diagnosis |
No BM at diagnosis |
|
||||||
|
N = 2,708 |
N = 1,198 |
N = 1,510 |
|
N = 1,694 |
N = 1,014 |
|
||||||
|
(44.2%) |
(55.8%) |
(62.6%) |
(37.4%) |
|||||||||
| N | Col% | N | Col% | N | Col% | P-value | N | Col% | N | Col% | P-value | |
|
Post-diagnosis resource utilization (i.e., till end of follow-up) |
|
|
|
|
|
|
|
|
|
|
|
|
| Bone mineral density (BMD) |
109 |
4.0 |
40 |
3.3 |
69 |
4.6 |
0.11 |
71 |
4.2 |
38 |
3.8 |
0.57 |
| Test | ||||||||||||
| PSA test |
2,148 |
79.3 |
906 |
75.6 |
1,242 |
82.3 |
<0.01 |
1,389 |
82.0 |
759 |
74.9 |
<0.01 |
| Oncologist visit |
1,681 |
62.1 |
857 |
71.5 |
824 |
54.6 |
<0.01 |
1,041 |
61.5 |
640 |
63.1 |
0.39 |
| Nuclear medicine specialist |
NR |
NR |
NR |
+ |
NR |
- |
0.07 |
NR |
>0 |
NR |
0.0 |
0.01 |
| Visit | ||||||||||||
| Radiation oncologist visit |
1,066 |
39.4 |
528 |
44.1 |
538 |
35.6 |
<0.01 |
687 |
40.6 |
379 |
37.4 |
0.10 |
| Bone biopsy |
79 |
2.9 |
62 |
5.2 |
17 |
1.1 |
<0.01 |
47 |
2.8 |
32 |
3.2 |
0.57 |
| Bone or joint imaging |
2,200 |
81.2 |
1,006 |
84.0 |
1,194 |
79.1 |
<0.01 |
1,406 |
83.0 |
794 |
78.3 |
<0.01 |
|
Treatment receipt (Part B) |
|
|
|
|
|
|
|
|
|
|
|
|
| Radiation |
889 |
32.8 |
445 |
37.2 |
444 |
29.4 |
<0.01 |
581 |
34.3 |
308 |
30.4 |
0.04 |
| External Beam radiation |
839 |
31.0 |
425 |
35.5 |
414 |
27.4 |
<0.01 |
553 |
32.6 |
286 |
28.2 |
0.02 |
| Therapy | ||||||||||||
| Radiopharmaceutical therapy |
91 |
3.4 |
60 |
5.0 |
31 |
2.1 |
<0.01 |
72 |
4.3 |
19 |
1.9 |
<0.01 |
| Bisphosphonates IV |
862 |
31.8 |
494 |
41.2 |
368 |
24.4 |
<0.01 |
593 |
35.0 |
269 |
26.5 |
<0.01 |
| Erythropoietin |
535 |
19.8 |
274 |
22.9 |
261 |
17.3 |
<0.01 |
352 |
20.8 |
183 |
18.1 |
0.08 |
| Opioids (moderate-severe) |
624 |
23.0 |
248 |
20.7 |
376 |
24.9 |
0.01 |
379 |
22.4 |
245 |
24.2 |
0.28 |
| |
|
Claims Approach 3 |
SEER measure |
|||||||||
|
Full M1 sample |
Concurrent BM |
No concurrent BM |
|
BM at diagnosis |
No BM at diagnosis |
|
||||||
|
N = 2,708 |
N = 1,198 |
N = 1,510 |
|
N = 1,694 |
N = 1,014 |
|
||||||
|
(44.2%) |
(55.8%) |
(62.6%) |
(37.4%) |
|||||||||
|
N |
Col% |
N |
Col% |
N |
Col% |
P-value |
N |
Col% |
N |
Col% |
P-value |
|
|
Resource utilization during the 90-day diagnosis period |
|
|
|
|
|
|
|
|
|
|
|
|
| PSA test |
1,629 |
60.2 |
698 |
58.3 |
931 |
61.7 |
0.07 |
1,046 |
61.8 |
583 |
57.5 |
0.03 |
| Bone biopsy |
65 |
2.4 |
NR |
+ |
NR |
- |
<0.01 |
42 |
2.5 |
23 |
2.3 |
0.73 |
| Bone or joint imaging |
2,009 |
74.2 |
999 |
83.4 |
1,010 |
66.9 |
<0.01 |
1,317 |
77.7 |
692 |
68.2 |
<0.01 |
| |
Mean |
S.D. |
Mean |
S.D. |
Mean |
S.D. |
p-value |
Mean |
S.D. |
Mean |
S.D. |
p-value |
|
Post-diagnosis resource utilization (i.e., till end of follow-up) |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of BMD tests |
0.04 |
0.21 |
0.03 |
0.19 |
0.05 |
0.22 |
0.09 |
0.04 |
0.22 |
0.04 |
0.19 |
0.39 |
| Number of PSA tests |
8.16 |
10.01 |
8.26 |
10.77 |
8.08 |
9.38 |
0.63 |
8.81 |
10.41 |
7.07 |
9.21 |
<0.01 |
| Number of PSA tests among patients with PSA tests |
10.29 |
10.23 |
10.93 |
11.15 |
9.82 |
9.47 |
0.02 |
10.75 |
10.56 |
9.44 |
9.54 |
<0.01 |
| Number of bone biopsies |
0.03 |
0.18 |
0.05 |
0.24 |
0.01 |
0.11 |
<0.01 |
0.03 |
0.18 |
0.03 |
0.19 |
0.53 |
| Number of bone or joint imaging |
1.65 |
1.58 |
1.67 |
1.56 |
1.64 |
1.61 |
0.60 |
1.73 |
1.61 |
1.52 |
1.53 |
<0.01 |
|
Resource utilization during the 90-day diagnosis period |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of PSA tests |
0.89 |
0.92 |
0.92 |
1.01 |
0.86 |
0.84 |
0.07 |
0.92 |
0.94 |
0.83 |
0.89 |
0.01 |
| Number of bone biopsies |
0.02 |
0.16 |
0.05 |
0.23 |
0.003 |
0.06 |
<0.01 |
0.03 |
0.17 |
0.02 |
0.15 |
0.60 |
| Number of bone or joint imaging | 0.76 | 0.47 | 0.86 | 0.42 | 0.68 | 0.49 | <0.01 | 0.79 | 0.44 | 0.70 | 0.49 | <0.01 |
NR, Not reported due to small sample size, per data use agreement; ‘+’ means that the column% is greater than the percentage for the full sample while ‘-‘ means that the column% is smaller than the percentage for the full sample.